Novel treatment (new drug/intervention; established drug/procedure in new situation)
Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis
1 University of California, San Francisco, 320 Lake Merced Blvd, #12, Daly City, California, 94015, USA
2 University of California, San Francisco, Ophthalmology, 3939 J St. #104, Sacramento, California, 95819, USA
3 University of California, San Francisco, Ophthalmology, Box 0730, 10 Kirkham K207, UCSF, San Francisco, California, 94143, USA
4 University of California, San Francisco, Ophthalmology, Box 0730, 10 Koret Way K231, UCSF, San Francisco, California, 94143, USA
Correspondence to:
Joan O’Brien, ObrienJ{at}vision.ucsf.edu
Primary acquired melanosis (PAM) with atypical cytological features has nearly a 50% chance of progressing to malignant melanoma. Surgical excision with cryotherapy has been the mainstay of treatment, but topical treatment with mitomycin C (MMC) is an increasingly common alternative treatment. Since PAM is relatively rare and MMC is a new treatment option, publications are limited to case reports and a few small series. Optimum doses, duration and timing of treatment cycles have not been established. Two patients were diagnosed with PAM with atypia and were treated with either primary or adjuvant treatment of 0.02% MMC for approximately 10 days for three cycles, which is the lowest dose protocol published to date for the treatment of PAM. Both patients showed stable partial response and only experienced temporary ocular drug toxicity.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Add article to my folders
- Download to citation manager
- Request Permissions
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full text of all Editor's Choice articles and summaries of every article are free without registration
The full text of Images in ... articles are free to registered users
Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource
Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog
